MEPRON

LOE Approaching

atovaquone

GSK
NDAORALSUSPENSIONPriority Review
Approved
Feb 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4

Mechanism of Action

[see Microbiology ()] .

Pharmacologic Class:

Antimalarial

Indications (7)

Pneumocystis jirovecii pneumonia (PCP) in adultsadolescents (aged 13 yearsolder)adolescents aged 13 yearsoldermild-to-moderate PCP in adultssevere PCP (alveolar arterial oxygen diffusion gradient [(A-a)DO 2 ] >45 mm Hg) with MEPRON has not been studied

Clinical Trials (4)

NCT04648033Phase 1Completed

Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC

Started Dec 2020
21 enrolled
Locally Advanced Non-Small Cell Lung Cancer
NCT01858831Phase 1Completed

Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension

Started Apr 2012
30 enrolled
Malaria
NCT00084227Phase 2/3Completed

Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America

Started Jul 2004
244 enrolled
Malaria, Falciparum
NCT00000802Phase 3Completed

A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides

Company
GSK
GSK
LONDON, United Kingdom
670 open jobs
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers